Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6Y7W6
UPID:
GGYF2_HUMAN
Alternative names:
PERQ amino acid-rich with GYF domain-containing protein 2; Trinucleotide repeat-containing gene 15 protein
Alternative UPACC:
Q6Y7W6; A6H8W4; B9EG55; E9PBB0; O75137; Q7Z2Z8; Q7Z3I2; Q96HU4; Q9NV82
Background:
GRB10-interacting GYF protein 2 (GIGYF2) plays a pivotal role in cellular processes by acting as a key component of the 4EHP-GYF2 complex, which represses translation initiation. It bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay, and is involved in regulating tyrosine kinase receptor signaling, including IGF1 and insulin receptors. Additionally, GIGYF2 assists in ribosome-associated quality control by sequestering mRNA caps, thus blocking ribosome initiation.
Therapeutic significance:
While the direct association of GIGYF2 with Parkinson disease 11 remains uncertain, understanding its complex role in cellular signaling and protein synthesis regulation could unveil novel therapeutic strategies, particularly in neurodegenerative disorders.